A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer

Deborah Citrin, Kevin Camphausen, Bradford J. Wood, Martha Quezado, John Denobile, James F. Pingpank, Richard E. Royal, H. Richard Alexander, Geoffrey Seidel, Seth M. Steinberg, Yvonne Shuttack, Steven K. Libutti

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Objective: The purpose of this pilot study was to evaluate the feasibility and tolerability of weekly intratumoral TNFerade™ injections combined with concurrent capecitabine and radiotherapy in the treatment of patients with locally advanced rectal cancer. Methods: Patients with T3, T4, or N+ rectal cancer received radiotherapy to a total dose of 50.4-54 Gy in combination with capecitabine 937.5 mg/m2 p.o. b.i.d. TNFerade™ at a dose of 4 × 1010 particle units was injected into the rectal tumor on the first day of radiotherapy and weekly for a total of 5 injections. Surgery was performed 5-10 weeks after the completion of chemoradiation. Results: Nine patients were enrolled in this pilot trial. The stage was cT2 in 2 patients, cT3 in 6 patients, cT4 in 1 patient, N- in 7 patients and N+ in 2 patients. Eight patients completed all treatments. Grade 3 hematologic toxicity was observed in 2 patients. There was no toxicity directly attributable to the injection procedure. A complete pathologic response was observed in 2 of 9 patients. Conclusions: This study demonstrates the feasibility of weekly intratumoral TNFerade™ injections during chemoradiotherapy for locally advanced rectal cancer. Pathologic responses with this combination compare favorably to published rates.

Original languageEnglish (US)
Pages (from-to)382-388
Number of pages7
JournalONCOLOGY
Volume79
Issue number5-6
DOIs
StatePublished - Apr 2011

Keywords

  • Neoadjuvant
  • Radiation
  • Rectal carcinoma
  • TNFerade™

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Citrin, D., Camphausen, K., Wood, B. J., Quezado, M., Denobile, J., Pingpank, J. F., Royal, R. E., Alexander, H. R., Seidel, G., Steinberg, S. M., Shuttack, Y., & Libutti, S. K. (2011). A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. ONCOLOGY, 79(5-6), 382-388. https://doi.org/10.1159/000323488